Skip to main content

Table 3 Best response by final daily dose of pomalidomide

From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Variable

Final daily dose of pomalidomidea

4 mg (n = 27)

3 mg (n = 7)

2 mg (n = 2)

Best response rate, n (%)

 Overall response

12 (44.4)

3 (42.9)

0

  Complete response

1 (3.7)

0

0

  Very good partial response

0

0

0

  Partial response

11 (40.7)

3 (42.9)

0

 Stable disease

11 (40.7)

3 (42.9)

2 (100)

 Progressive disease

4 (14.8)

1 (14.3)

0

  1. aDaily dose as of February 3, 2015